MaxCyte, Inc. (MXCT): Price and Financial Metrics
MXCT Price/Volume Stats
| Current price | $3.55 | 52-week high | $5.55 |
| Prev. close | $3.45 | 52-week low | $3.16 |
| Day low | $3.39 | Volume | 516,900 |
| Day high | $3.63 | Avg. volume | 521,448 |
| 50-day MA | $3.73 | Dividend yield | N/A |
| 200-day MA | $4.17 | Market Cap | 374.46M |
MXCT Stock Price Chart Interactive Chart >
MaxCyte, Inc. (MXCT) Company Bio
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
MXCT Price Returns
| 1-mo | -6.58% |
| 3-mo | -18.39% |
| 6-mo | N/A |
| 1-year | -24.15% |
| 3-year | -61.29% |
| 5-year | N/A |
| YTD | -24.47% |
| 2023 | -13.92% |
| 2022 | -46.42% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...